Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MI-503 是一种高效且可口服的 menin-mLL 相互作用抑制剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 529 | 现货 | ||
5 mg | ¥ 995 | 现货 | ||
10 mg | ¥ 1,917 | 现货 | ||
25 mg | ¥ 2,620 | 现货 | ||
50 mg | ¥ 3,890 | 现货 | ||
100 mg | ¥ 5,580 | 现货 | ||
200 mg | ¥ 8,450 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,364 | 现货 |
产品描述 | MI-503 is a highly effective and orally bioavailable inhibitor of the menin-mLL interaction. |
靶点活性 | Menin-MLL:4.7 nM (cell free) |
体外活性 | Treatment of murine bone marrow cells (BMC) transformed with the mLL-AF9 oncogene with MI-503 results in substantial growth inhibition (GI50: 0.22 μM). The cell growth inhibitory effect of MI-503 is time-dependent, with a pronounced effect achieved after 7-10 days of treatment. |
体内活性 | MI-503 achieves high level in peripheral blood following a single intravenous or oral dose, while also showing high oral bioavailability (75%). MI-503 induces strong inhibition of tumor growth with once-daily intraperitoneal (i.p.) administration. Treatment with MI-503 results in an over 80% reduction in MV4;11 tumor volume and complete tumor regression in two mice. Ten consecutive days of treatment with MI-503 results in a marked delay in progression of mLL leukemia in mice and significantly reduces leukemia tumor burden. Treatment with MI-503 and MI-463 leads to markedly reduced expression of Hoxa9 and Meis1. |
细胞实验 | Leukemia cells are treated with MI-503 or 0.25% DMSO and cultured at 37 °C for 7 days. Media is changed on day 4, viable cell numbers are restored to the original concentration and MI-503 are re-supplied. MTT cell proliferation assay kit is then employed, and plates are read for absorbance at 570 nm using a microplate reader. |
动物实验 | For efficacy studies in MV4;11 subcutaneous xenograft mice model, 5×10^6 cells are injected into the 4-6 week old female BALB/c nude mice. Treatment is started when the tumor size reached ~100 mm^3. Vehicle (25% DMSO, 25% PEG400, 50% PBS) or compounds (MI-463 or MI-503) are administrated once daily at designated doses using i.p. injections. |
化合物与蛋白结合的复合物 |
Menin in complex with MI-503 |
分子量 | 564.63 |
分子式 | C28H27F3N8S |
CAS No. | 1857417-13-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 45 mg/mL (79.7 mM), Sonication is recommended.
H2O: Insoluble
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.7711 mL | 8.8554 mL | 17.7107 mL | 44.2768 mL |
5 mM | 0.3542 mL | 1.7711 mL | 3.5421 mL | 8.8554 mL | |
10 mM | 0.1771 mL | 0.8855 mL | 1.7711 mL | 4.4277 mL | |
20 mM | 0.0886 mL | 0.4428 mL | 0.8855 mL | 2.2138 mL | |
50 mM | 0.0354 mL | 0.1771 mL | 0.3542 mL | 0.8855 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
MI-503 1857417-13-0 Chromatin/Epigenetic Epigenetic Reader Domain Histone Methyltransferase Inhibitor inhibit MI 503 MI503 inhibitor